Jakafi Shows Power Against Earlier Treatment for Myelofibrosis

patientpower has 2398 videos Subscribe Here

Description: The JAK 1 and JAK 2 inhibitor, Jakafi (ruxolitinib), is proving itself to be more effective than hydroxyurea as a treatment for the symptoms of myelofibrosis, according to new, longer-term data released at the 2012 American Society of Hematology meeting (ASH) in Atlanta. The new drug also appears to extend survival. A key investigator of the study, Dr. Francisco Cervantes, from Hospital Clinic in Barcelona, explains the results in an interview with Andrew Schorr.
Shared By : patientpower
Posted on : 12/21/12
Added : 5 years ago
Category : General